United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,265 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $119.40, for a total value of $151,041.00. Following the completion of the sale, the chief executive officer now directly owns 1,405 shares of the company’s stock, valued at approximately $167,757. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

United Therapeutics Co. (NASDAQ:UTHR) traded up 0.63% on Friday, hitting $119.08. The company’s stock had a trading volume of 561,393 shares. The firm has a 50 day moving average of $121.95 and a 200 day moving average of $138.72. United Therapeutics Co. has a 12 month low of $97.52 and a 12 month high of $169.89. The firm has a market cap of $5.37 billion, a price-to-earnings ratio of 8.36 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.12 by $0.77. United Therapeutics had a net margin of 44.40% and a return on equity of 41.78%. The firm had revenue of $370.50 million during the quarter, compared to the consensus estimate of $399.59 million. During the same quarter in the previous year, the firm posted $3.02 earnings per share. The company’s revenue was up .4% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Co. will post $14.42 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/05/26/martine-a-rothblatt-sells-1265-shares-of-united-therapeutics-co-uthr-stock.html.

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in United Therapeutics by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after buying an additional 4,632,287 shares in the last quarter. Norges Bank bought a new stake in United Therapeutics during the fourth quarter valued at $63,975,000. Russell Investments Group Ltd. bought a new stake in United Therapeutics during the fourth quarter valued at $61,510,000. Consonance Capital Management LP increased its stake in United Therapeutics by 95.5% in the third quarter. Consonance Capital Management LP now owns 818,700 shares of the biotechnology company’s stock valued at $96,672,000 after buying an additional 400,000 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in United Therapeutics by 27.8% in the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock valued at $235,068,000 after buying an additional 377,395 shares in the last quarter.

A number of equities research analysts have recently weighed in on UTHR shares. Credit Suisse Group AG started coverage on United Therapeutics in a research note on Thursday, March 16th. They issued an “underperform” rating and a $120.00 target price for the company. Cowen and Company downgraded United Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $140.00 to $121.00 in a report on Monday, April 3rd. HC Wainwright restated a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a report on Monday, April 17th. Wedbush restated an “outperform” rating and set a $229.00 price target on shares of United Therapeutics in a report on Tuesday, April 4th. Finally, Jefferies Group LLC restated a “sell” rating and set a $116.00 price target on shares of United Therapeutics in a report on Wednesday, April 12th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $137.09.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

12 Month Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.